View Older Stories View More Recent Stories
-
Roth Capital Upgrades Golden Minerals Company (AUMN) to Buy
-
PlacementTracker Publishes Third Quarter 2014 PIPE Market League Tables
-
Cytori Therapeutics (CYTX) Announces $13.5M Registered Direct Placement
-
Roth Capital Cuts SodaStream International (SODA) to Neutral
-
Notable Analyst Rating Changes 10/7: (IR) (ADHD) (AAPL) Upgraded; (SNSS) (DE) (CBSH) Downgraded
-
Roth Keeps Regeneron (REGN) at 'Buy'; Another Eylea Approval is No Surprise
-
Roth Capital Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Neutral
-
Trina Solar (TSL) Closes 10.3M ADS, $115M Conv. Notes Offerings
-
Roth Capital Affirms SolarCity (SCTY) at 'Buy'; Comments on Recent Meetings with Management
-
Roth Capital Starts ContraFect Corp. (CFRX) at Buy; Market Missing Potential Impact of Bacteriophage Lysins
-
Recent Moves by Curis (CRIS) May Increase Value of CUDC-907 - Roth Capital
-
Trina Solar (TSL) Prices 10.3M ADS, $100M Conv. Notes Offering
-
Lerge Commercial Exit by RGS Energy (RGSE) is 'Right Move' - Roth
-
Latest Data for Regeneron's (REGN) Dupilumab Broadens Benefit Profile - Roth
-
Roth Lowers Ests on Galena Biopharma (GALE) Following Special Committee Report
-
Streetinsider.com's Hot Lunchtime Reads 9/29: (AAPL) (JACK) (BLRXX) (TSLA)
-
Daiichi Sankyo, Ambit (AMBI) Deal is Positive for BioLineRx (BLRX) - Roth Capital
-
Roth Maintains Keryx Biopharma (KERX) at Buy Following Initiation of Ferric Citrate Phase 2
-
Roth Capital Starts Super Micro Computer (SMCI) at Buy
-
Roth Capital Downgrades AcelRx Pharmaceuticals (ACRX) to Neutral
-
Roth 'Encouraged' by Rexahn's (RNN) RX-3117 Receiving FDA Orphan Drug Designation; Offers Commentary
-
Roth Comments on ImmunoCellular's (IMUC) Licensing Agreement with Caltech; Affirms at 'Buy'
-
Roth Positive on SolarCity (SCTY) Following Closure of Silevo Deal; Affirms 'Buy' Rating
-
Roth Comments on TG Therapeutics' (TGTX) TGR-1202 Licensing Announcement
-
Roth Capital Downgrades Concur Technologies (CNQR) to Neutral
-
Roth Capital Starts Bluebird Bio (BLUE) at Buy
-
Sky Solar Holdings, Ltd. (SKYS) Files $100M IPO
-
Roth Capital Starts Ideal Power (IPWR) at Buy
-
Roth Capital Starts CymaBay Therapeutic (CBAY) at Buy
-
Roth 'Encouraged' by Spectrum's (SPPI) Licensing Agreement with CASI Pharma (CASI)
-
Streetinsider.com's Hot Lunchtime Reads 9/17: (ATVI) (NKE) (AAPL) (BLRX)
-
Preclinical BioLineRx (BLRX) BL-8040 Data on AML is Encouraging - Roth Capital
-
Roth Comments on Concert's (CNCE) Initiation of CTP-730 Phase 1
-
Roth Comments on ImmunoCellular (IMUC) Following ICT-107 Updates; Affirms 'Buy' Rating
-
Roth Sees 'Significant' and 'Impressive' Cost Efficiencies in TG Therapeutics' (TGTX) CLL Combo Phase 3
-
Roth Keeps Concert Pharma (CNCE) at 'Buy'; AVP-923 Phase 2 Data is Encouraging (AVNR)
-
Roth Commments on TG Therapeutics (TGTX); FDA Grants TG-1101 SPA in CLL Patients
-
Inventure Foods Announces Pricing of Public Offering by Selling Stockholder
-
Notable 52-Week Highs and Lows of the Day 9/11: (PANW) (LE) (MTN) High; (DLIW) (EOPN) (XNY) Low
-
Notable Analyst Rating Changes 9/11: (VRA) (WCC) (AAWW) Upgraded; (M) (EOPN) (ESRX) Downgraded
-
Roth Capital Starts Palo Alto Networks (PANW) at Buy
-
Roth Keeps Ligand (LGND) at 'Buy' Following New Captisol-Based Tech Launch
-
Roth Capital Starts Good Times Restaurants (GTIM) at Buy
-
Key Items for SolarCity (SCTY) Following Vivint Solar (VSLR) IPO Filing
-
Roth Raises PT on Keryx Biophama (KERX) to $32 Following Ferric Citrate Approval
-
Roth Capital Starts Cherokee Inc. (CHKE) at Buy
-
Roth Comments on China Solar Following Release of China's Updated NEA Policy for DG Solar (CSIQ) (JASO) (JKS) (TSL)
-
Inventure Foods (SNAK) Announces 3.3M Common Secodary Offering
-
Inventure Foods Announces Commencement of Public Offering by Selling Stockholder
-
Infinity (INFI) News a Positive for TG Therapeutics (TGTX) - Roth Capital

